PT2399 is a novel, potent, and orally bioavailable small molecule inhibitor of HIF-2 which binds to HIF-2α PAS B domain with an IC50 of 6 nM, exhibiting potent antitumor activity in vivo.. It selectively disrupts the heterodimerization of HIF-2α with HIF-1β. Preclinical and clinical data indicate that PT2399 is effective in blocking cancer cell growth, proliferation, and tumor angiogenesis characteristic in ccRCC.

纯度：≥98%

CAS：1672662-14-4